Myeloid Maturity: ATRA to Enhance Anti-PD-1?

Clin Cancer Res. 2023 Apr 3;29(7):1167-1169. doi: 10.1158/1078-0432.CCR-22-3652.

Abstract

Myeloid-derived suppressor cells (MDSC) are associated with resistance to anti-PD-1 therapies. All-trans retinoic acid (ATRA) may induce maturation of MDSCs and alter their immunosuppressive effects. Adding ATRA to pembrolizumab may target this resistance mechanism to enhance the overall impact of anti-PD-1-based immunotherapy. See related article by Tobin et al., p. 1209.

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Cell Differentiation / drug effects
  • Humans
  • Melanoma* / drug therapy
  • Myeloid-Derived Suppressor Cells* / drug effects
  • Tretinoin / pharmacology
  • Tretinoin / therapeutic use

Substances

  • pembrolizumab
  • Tretinoin